Global Bioabsorbable Stents (BAS) Pipeline Report 2023: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com

2023-05-24
Business Wire
财报
DUBLIN--(BUSINESS WIRE)--The "Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering.
'Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update'
The report provides comprehensive information about the Bioabsorbable Stents (BAS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Bioabsorbable stents are also known as bioreabsorbable or biodegradable coronary stents. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents.
Scope
Extensive coverage of the Bioabsorbable Stents (BAS) under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment/industry
Reasons to Buy
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Bioabsorbable Stents (BAS) Overview
3 Products under Development
3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory
3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies
4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
5 Bioabsorbable Stents (BAS) Companies and Product Overview
5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
5.3 Arterius Ltd Company Overview
5.5 Biosten, LLC Company Overview
5.6 Biotronik AG Company Overview
5.7 Biotronik SE & Co KG Company Overview
5.8 Biotyx Medical (Shenzhen) Co Ltd Company Overview
5.10 Cardionovum GmbH Company Overview
5.11 Cordis Corp Company Overview
5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
5.13 Icon Interventional Systems, Inc. Company Overview
5.14 Japan Stent Technology Co., Ltd. Company Overview
5.15 Kyoto Medical Planning Co Ltd Company Overview
5.17 Manli Cardiology Ltd Company Overview
5.20 Michigan Technological University Company Overview
5.22 Minvasys SAS Company Overview
5.24 NanoCoeur, Inc. Company Overview
5.25 North Carolina State University Company Overview
5.26 Northwestern University Company Overview
5.27 OrbusNeich Company Overview
5.28 Pediastent LLC Company Overview
5.29 QualiMed Innovative Medizinprodukte GmbH Company Overview
5.33 Shanghai Healing Medical Instruments Co Ltd Company Overview
5.34 Tepha Inc Company Overview
5.35 Tremedics Medical Devices LLC Company Overview
5.36 UAB Minority Health and Health Equity Research Center Company Overview
5.37 University of Florida Company Overview
5.38 University of Strathclyde Company Overview
5.39 VasoTech Inc. Company Overview
5.40 Xenogenics Corporation Company Overview
6 Bioabsorbable Stents (BAS)- Recent Developments
6.1 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
6.2 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023
6.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022
6.4 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022
6.5 Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule
6.6 Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022
6.7 Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022
7 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/d7bf3z
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。